These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17666487)
1. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Berthiaume M; Laplante M; Festuccia WT; Cianflone K; Turcotte LP; Joanisse DR; Olivecrona G; Thieringer R; Deshaies Y Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1045-52. PubMed ID: 17666487 [TBL] [Abstract][Full Text] [Related]
2. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Berthiaume M; Laplante M; Festuccia WT; Berger JP; Thieringer R; Deshaies Y Int J Obes (Lond); 2009 May; 33(5):601-4. PubMed ID: 19223847 [TBL] [Abstract][Full Text] [Related]
3. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. Livingstone DE; Walker BR J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365 [TBL] [Abstract][Full Text] [Related]
4. Dexamethasone facilitates lipid accumulation and mild feed restriction improves fatty acids oxidation in skeletal muscle of broiler chicks (Gallus gallus domesticus). Wang X; Lin H; Song Z; Jiao H Comp Biochem Physiol C Toxicol Pharmacol; 2010 May; 151(4):447-54. PubMed ID: 20138241 [TBL] [Abstract][Full Text] [Related]
5. Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Berthiaume M; Laplante M; Festuccia WT; Berger JP; Thieringer R; Deshaies Y Metabolism; 2010 Jan; 59(1):114-7. PubMed ID: 19766266 [TBL] [Abstract][Full Text] [Related]
6. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115 [TBL] [Abstract][Full Text] [Related]
7. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Nuotio-Antar AM; Hachey DL; Hasty AH Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220 [TBL] [Abstract][Full Text] [Related]
8. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Berthiaume M; Laplante M; Festuccia W; Gélinas Y; Poulin S; Lalonde J; Joanisse DR; Thieringer R; Deshaies Y Endocrinology; 2007 May; 148(5):2391-7. PubMed ID: 17272400 [TBL] [Abstract][Full Text] [Related]
9. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia. Berthiaume M; Laplante M; Tchernof A; Deshaies Y Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631 [TBL] [Abstract][Full Text] [Related]
10. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468 [TBL] [Abstract][Full Text] [Related]
12. Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity. Liu Y; Sun WL; Sun Y; Hu G; Ding GX Acta Pharmacol Sin; 2006 May; 27(5):588-96. PubMed ID: 16626514 [TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Stimson RH; Walker BR Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154 [TBL] [Abstract][Full Text] [Related]